Uppsala 15th April 2019


Nanexa has had a good start to the year

The first quarter of 2019 has been an intensive quarter for us at Nanexa. With the three agreements we signed at the end of last year, we have been fully committed to delivering in those collaborations. We have additional activities to complete to finalize these initial evaluations of PharmaShell® for each company’s active substances, but discussions are already underway about possible continuations.

The work with AstraZeneca is also proceeding according to plan, and another animal study has been started under their auspices as part of the widening of the collaboration that was communicated during the autumn of 2018.

In parallel with the above, we have continued to work in the NEX-18 project. We conducted our first animal study with PharmaShell® coated azacitidine and generated valuable data to optimize the PharmaShell® process to the target profile for drug release.

Work to develop regulatory and clinical development strategy for NEX-18 is underway for both the European and American markets. Our goal is to create the shortest and most cost-effective development plan possible.

In the Uppsala laboratory, we also installed our third ALD reactor during the first quarter and expanded our capacity with additional analytical equipment. We have now also strengthened our group with another employee with a master’s degree in materials chemistry, who will strengthen our capacity for the development of PharmaShell®.

On the commercial side we have visited two conferences; partly Drug Delivery Partnerships in Florida in January and BIO-Europe in Vienna in March. During the conferences we have had many good meetings and discussions with interesting pharmaceutical companies.

It can also be mentioned that for the first time Nanexa and PharmaShell® are highlighted in a global market analysis of new drug delivery technologies for biologics – “Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030” (Roots analysis, Business research and consulting).


Nanexa’s CEO David Westberg comments:

It has been a really good start to the year and really fun that we get noticed in external market reports. It is gratifying that the partnerships we have done really well and that we have been able to deliver according to agreed plans with the partners. I feel very confident that the rest of the year will follow in the same positive direction.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.